Gastric Cancer TumorGraft3D Screen

Ideal Translational Investigation: Ex Vivo TumorGraft3D Models

Evaluate gastric cancer therapeutics' using our biobank of meticulously characterized 3D organ-like tumor models derived from low-passage patient-derived xenograft (PDX) models. These TumorGraft3D models accurately replicate an organ-like tumor microenvironment, including heterogeneity and patient diversity, and utilizes a distinct matrix-free assay with indication-specific media, ensuring precise biological relevance and retaining key cancer molecular characteristics.

Our gastric cancer ex vivo TumorGraft3D screen also features models pretreated with the latest cancer therapies, such as Her2+ models pretreated with trastuzumab (CTG-3027 and CTG-3033), and a signet ring cell model (CTG-1234), closely reflecting real-world patient responses. This approach aids in identifying the most promising candidates for subsequent in vivo studies.

Champions' Gastric Cancer TumorGraft3D Screen offers:

• Comprehensive model characterization (stored in Lumin) with:
          ☑️Robust clinical data annotations
          ☑️NGS (RNAseq and WES) analysis
          ☑️Proliferation data
• Endpoint Analysis: CellTiter-Glo^® data for assessing cell viability and proliferation, with an option of incorporating high-content imaging analysis.
• Versatile Assay Capabilities: Our assay enables the ranking of different test agents' effects across a series of models, exploration of tumor cell biology and interactions with the tumor microenvironment, and evaluation of therapeutic agent synergy in experimental combinations.
• Expanded Analysis Opportunities: DRUG-seq and Luminex endpoint analyses are available for additional evaluation, offering deeper understanding at an extra cost.
• Tailored Bioinformatics Solutions: We offer custom bioinformatics analysis and NGS data licensing upon request, ensuring personalized insights to meet your specific research needs.
• Cost-Effective Solution: Our services are designed to save costs compared to standalone studies, offering a budget-friendly yet comprehensive approach to your research objectives.
• 50% off of a Standard of Care agent arm (selected by Champions) and no minimum number of models to enroll, and you can select the models you want to screen.